Losing weight can cure obstructive sleep apnea in overweight

A new study shows that losing weight is perhaps the single most effective way to reduce OSA symptoms and associated disorders. – Losing weight is perhaps the single most effective way to reduce obstructive sleep apnea OSA symptoms and associated disorders in sufferers of obstructive sleep apnea (OSA).

GSK’s alli for weight loss approved in Europe

GlaxoSmithKline receives European Commission approval to market alli? (orlistat 60mg) – A decision made by the European Commission opens access to a treatment that could help people who are overweight and obese.

Human clinical trial of embryonic stem cell therapy approved

Geron Receives FDA Clearance to Begin World’s First Human Clinical Trial of Embryonic Stem Cell-Based Therapy. Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury. – Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.

Anxious older adults may benefit from antidepressants

Anxious older adults sufferring from an anxiety disorders may benefit from antidepressants – Many older adults worry – a lot. Almost one in 10 Americans over age 60 suffer from an anxiety disorder that causes them to worry excessively about normal things – like health, finances, disability and family.

Gardasil approval delayed for use in women ages 27 – 45

Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL? in Women Ages 27 through 45 – Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

Asthma patients may get benefit from antifungal drug

Some patients with severe asthma who also have allergic sensitivity to certain fungi enjoy great improvements in their quality of life and on other measures after taking an antifungal drug. – Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found.

Latisse approved for hypotrichosis of eyelashes

Allergan Announces U.S. Food and Drug Administration (FDA) Approval of LATISSE(TM) — First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes. New Prescription Product Increases Length, Thickness and Darkness of Eyelashes. – Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.

38% adults and 12% children use complementary and alternative medicine

US Government survey shows 38 percent of adults and 12 percent of children use complementary and alternative medicine – Approximately 38 percent of adults in the United States aged 18 years and over and nearly 12 percent of U.S. children aged 17 years and under use some form of complementary and alternative medicine (CAM), according to a new nationwide government survey.

HPV vaccine’s hypersensitivity reactions are rare

Allergy and immunology consultant Liew Woei Kang and colleagues found that true hypersensitivity to the quadrivalent human papillomavirus vaccine was uncommon, and most girls in Australian schools tolerated subsequent doses. – Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.

Gardasil HPV vaccine prevented genital lesions in men

GARDASIL?, Merck’s Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.